PepGen IncNASDAQ:PEPG
- LAST PRICE11.7200
- TODAY'S CHANGE (%)0.3300 (2.8973%)
- Bid / Lots6.2000/ 1
- Ask / Lots13.5000/ 1
- Open / Previous Close11.3900 / 11.3900
- Day Range
- 52 Week Range
- Volume14,316
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PEPG |
|---|---|---|
| 09:32 ET | 255 | 11.49 |
| 09:34 ET | 300 | 11.44 |
| 10:32 ET | 137 | 11.375 |
| 12:54 ET | 100 | 11.54 |
| 12:59 ET | 345 | 11.585 |
| 01:46 ET | 377 | 11.61 |
| 02:20 ET | 100 | 11.765 |
| 02:40 ET | 100 | 11.67 |
| 03:18 ET | 418 | 11.795 |
| 03:30 ET | 225 | 11.8 |
| 03:43 ET | 200 | 11.73 |
| 03:45 ET | 100 | 11.8 |
| 03:48 ET | 100 | 11.65 |
| 03:56 ET | 800 | 11.64 |
| 03:57 ET | 354 | 11.68 |
| 03:59 ET | 400 | 11.72 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
PepGen Inc | 368.5M | -3.5x | --- |
Alto Neuroscience Inc | 366.7M | -9.8x | --- |
Fibrobiologics Inc | 353.7M | -12.1x | --- |
Aura Biosciences Inc | 351.0M | -3.7x | --- |
Biomea Fusion Inc | 388.7M | -3.2x | --- |
Tenaya Therapeutics Inc | 347.8M | -2.6x | --- |
Company Information
PepGen Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases. The Company’s pipeline consists of two clinical stage programs: PGN-EDO51 for duchenne muscular dystrophy (DMD) patients who are amenable to exon 51-skipping and PGN-EDODM1 for myotonic dystrophy type 1 (DM1) patients. It also has three additional preclinical stage programs: PGN-EDO53, PGN-EDO45 and PGN-EDO44.
Contact Information
- Headquarters
- 245 Main St, 2nd FloorCAMBRIDGE, MA, United States 02142
- Phone
- 703-456-8000
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Laurie Keating
- President, Chief Executive Officer, Treasurer, Secretary, Director
- James Mcarthur
- Chief Financial Officer
- Noel Donnelly
- Executive Vice President - Research and Preclinical Development
- Jaya Goyal
- Senior Vice President - Clinical Development
- Michelle Mellion
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $368.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 32.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.30 |
Book Value | $4.55 |
P/E Ratio | -3.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
